Who owns Xilio Therapeutics, Inc.?
Institutional ownership of XLO from SEC Form 13F filings across 15 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
15
13F holders
$6.0M
value, 2026 filers
9.5%
of shares outstanding (622,907 sh)
8
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30· % of fund = share of the manager's own book · % of co. = share of XLO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 178,517 | $1.7M | 0.0% | 2.7% | -27.8% |
| 2 | Sio Capital Management, LLC | 152,464 | $1.5M | 0.2% | 2.3% | 0.0% |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C.NEW | 111,541 | $1.1M | 0.0% | 1.7% | new |
| 4 | MORGAN STANLEY | 56,954 | $545,619 | 0.0% | 0.9% | -0.9% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 39,055 | $374,174 | 0.0% | 0.6% | +5.0% |
| 6 | CITADEL ADVISORS LLCNEW | 25,950 | $248,601 | 0.0% | 0.4% | new |
| 7 | VANGUARD FIDUCIARY TRUST CO | 22,594 | $216,451 | 0.0% | 0.3% | -20.7% |
| 8 | TWO SIGMA INVESTMENTS, LPNEW | 14,544 | $139,332 | 0.0% | 0.2% | new |
| 9 | PRELUDE CAPITAL MANAGEMENT, LLCNEW | 11,600 | $111,128 | 0.0% | 0.2% | new |
| 10 | BlackRock, Inc.NEW | 8,757 | $83,892 | 0.0% | 0.1% | new |
| 11 | Steward Partners Investment Advisory, LLCNEW | 714 | $6,840 | 0.0% | 0% | new |
| 12 | BARCLAYS PLCNEW | 115 | $1,102 | 0.0% | 0% | new |
| 13 | Key Financial Inc | 59 | $565 | 0.0% | 0% | 0.0% |
| 14 | JONES FINANCIAL COMPANIES LLLPNEW | 29 | $262 | 0.0% | 0% | new |
| 15 | UBS Group AG | 14 | $134 | 0.0% | 0% | -99.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.